Developing a population-based registry for patients with paraproteinemias or multiple myeloma

Ong, Francisca; Hermans, J.; Noordijk, E.M.; Kieviet, Wim de; Wijermans, P. W.; Seelen, P J; Snijder, Simone; Oostindiër, M.J.; Kluin-Nelemans, Hanneke C.

doi:10.1016/s0895-4356(97)00092-9

Cited by 11 publications

(7 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The frequency of newly discovered cases of paraproteinaemia in 1992 calculated from our registry was 31/100 000 inhabitants and 189/100 000 for people above 70 years of age (Ong et al, 1997b). To date, only the prevalence of paraproteinaemia has been reported (about 3% of patients aged over 70) (Axelsson et al, 1966;Kyle et al, 1972;Saleun et al, 1982;Bataille & Harousseau, 1997).…”

Section: Discussionmentioning

confidence: 81%

“…This registry enabled us to calculate the incidence of paraproteinaemia for the first time in a population-based setting. The frequency of multiple myeloma in 1992 was 4·5/100 000 for females and 4·8/100 000 for males (Ong et al, 1997b), although the actual incidence will be higher since multiple myeloma patients already harbouring a paraproteinaemia before 1991 had been excluded from the registry.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

A population‐based registry on paraproteinaemia in the Netherlands

Ong

Hermans

Noordijk³

et al. 1997

Br J Haematol

Self Cite

View full text Add to dashboard Cite

Patients with monoclonal gammopathies comprise a heterogenous group. The few studies on incidence and follow‐up are single‐centre‐based and may reflect referral bias. To avoid this, all patients (n = 1275) in mid‐western Netherlands with a newly discovered paraproteinaemia in 1991, 1992 and 1993 were included in a population‐based registry and divided into four major diagnostic groups: multiple myeloma and plasmacytoma (n = 230, 18%), other haematological diseases (n = 141, 11%), paraprotein‐related internal diseases (n = 191, 15%) and monoclonal gammopathy of undetermined significance (MGUS, n = 713, 56%). To avoid a possibly erroneous diagnosis, patients who were classified as having MGUS but who did not undergo confirmatory bone marrow examination were included in a separate group ‘provisional MGUS’ (n = 524, 41%), whereas patients who did were classified as having ‘definite MGUS’ (n = 189, 15%). The ‘provisional MGUS’ patients were relatively older and had more often a poor performance status, but differences between this and the ‘definite MGUS’ group were otherwise small. Patients complaining of general malaise more often had a full work‐up of their paraproteinaemia. Bone pain, hypercalcaemia, high total protein, and high ESR occurred predominantly in the myeloma group, whereas fever or infection was less often seen in these patients. This registry of patients with paraproteinaemias provided valuable data related to all different diseases associated with paraproteinaemia.

show abstract

Section: Discussionmentioning

confidence: 81%

Section: Discussionmentioning

confidence: 99%

A population‐based registry on paraproteinaemia in the Netherlands

Ong

Hermans

Noordijk³

et al. 1997

Br J Haematol

Self Cite

View full text Add to dashboard Cite

show abstract

“…In total, 1464 patients have been registered. The setup and contents of this registry have been described previously in [9,10].…”

Section: Patient Populationmentioning

confidence: 99%

Monoclonal proteinaemia and solid tumours

Schaar

2004

European Journal of Cancer

View full text Add to dashboard Cite

A higher prevalence of solid tumours in patients with M(onoclonal) proteinaemia without a co-existing haematological malignancy has been reported. We investigated this association by linking a population-based registry of patients with newly diagnosed M-proteinaemia (n ¼ 1464) with the Regional Cancer Registry. Patients were followed for a median of 7.4 years for those still alive. In total 167 (11%) patients with 173 solid tumours were compared with 861 patients with 'M-proteinaemia only' (without a haematological malignancy). The M-protein isotype or level or clinical parameters did not differ between the groups. M-protein isotype was not associated with a specific tumour type. Standardised Morbidity Ratios (SMR) for nearly all solid tumours were elevated in the year of the M-protein discovery, but the excess risk disappeared during follow-up suggesting selection through diagnostic investigations rather than a causal role. In this large series of patients with both newly diagnosed M-proteinaemia and a solid tumour no relationship could be established.

show abstract

“…Their clinical spectrum ranges from monoclonal gammopathy of undetermined significance (MGUS; a benign disorder characterized by monoclonal immunoglobulin level of <30 g/L and a percentage of plasma cells in bone marrow of <10%) to the full-blown disease multiple myeloma (MM). Other B lympho proliferative disorder associated with M-proteins include: waldenstrom̕s macro globulinemia, plasmacytoma, nonhodgkin lymphoma, chronic lymphocytic leukemia, primary, and heavy and light chain amyloidosis diseases [1,3]. MGUS are much more common than MM and their incidence is age dependent.…”

Section: Introductionmentioning

confidence: 99%

Monoclonal Gammopathy in Iran: Prevalence and Isotype Distribution

Sarrafnejad¹

2014

MOJI

View full text Add to dashboard Cite

Developing a population-based registry for patients with paraproteinemias or multiple myeloma

Cited by 11 publications

References 9 publications

A population‐based registry on paraproteinaemia in the Netherlands

A population‐based registry on paraproteinaemia in the Netherlands

Monoclonal proteinaemia and solid tumours

Monoclonal Gammopathy in Iran: Prevalence and Isotype Distribution

Contact Info

Product

Resources

About